Inclusion Criteria:

1. Biopsy proven clear cell kidney cancer with metastatic disease. Progressive disease
or intolerance to at least one prior systemic therapy

2. Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >/= 20 mm with conventional
techniques or as >/= 10 mm with spiral CT scan.

3. Age >/= 18 years

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

5. Adequate hepatic function with serum ALT serum direct bilirubin
6. Absolute neutrophil count (ANC) >/= 1.0 × 10^9/L; patients with an ECOG performance
status of 2 at study entry must have an ANC >/= 1.5 x 10^9/L

7. Hemoglobin >/= 8 g/dL (80 g/L) within 14 days prior to beginning study treatment
(subjects may be receiving red blood cell [RBC] transfusions in accordance with
institutional guidelines); Patients with an ECOG performance status of 2 at study
entry must have a hemoglobin >/= 9 g/dL (transfusion assistance acceptable)

8. Platelet count >/= 50 × 10^9/L; Patients with an ECOG performance status of 2 at
study entry must have a platelet count >/= 100 × 10^9/L

9. Creatinine clearance (CrCl) >/= 30 mL/minute, either measured or calculated using a
standard formula (eg, Cockcroft and Gault)

10. Written informed consent in accordance with federal, local, and institutional
guidelines.

11. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and
to practice contraception during the study and for a period of 6 weeks after you stop
receiving the study drug

12. Male subjects must agree to practice contraception during the study and for a period
of 6 weeks after you stop receiving the study drug

Exclusion Criteria:

1. Brain metastases not controlled with surgery, whole brain radiotherapy, or with
stereotactic radiosurgery

2. Systemic therapy within two weeks of treatment initiation

3. Pregnant or lactating females

4. Major surgery within 21 days prior to beginning study treatment

5. Acute active infection requiring treatment (systemic antibiotics, antivirals, or
antifungals) within 14 days prior to beginning study treatment

6. Known human immunodeficiency virus infection

7. Active hepatitis B or C infection

8. Unstable angina or myocardial infarction within 4 months prior to beginning study
treatment, NYHA Class III or IV heart failure, uncontrolled angina, history of severe
coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus
syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction
system abnormalities unless subject has a pacemaker

9. Uncontrolled hypertension (defined by BP consistently > 150/100) or uncontrolled
diabetes (defined by HbA1c > 8.5) within 14 days prior to beginning study treatment

10. Nonhematologic malignancy within the past 2 years with the exception of a) adequately
treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
less with stable prostate-specific antigen levels; or d) cancer considered cured by
surgical resection or unlikely to impact survival during the duration of the study,
such as localized transitional cell carcinoma of the bladder or benign tumors of the
adrenal or pancreas

11. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to
beginning study treatment

12. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
carfilzomib)

13. Contraindication to any of the required concomitant drugs or supportive treatments,
including hypersensitivity to all anticoagulation and antiplatelet options, antiviral
drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

14. Subjects with pleural effusions requiring thoracentesis or ascites requiring
paracentesis within 14 days prior to beginning study treatment

15. Any other clinically significant medical disease or condition that, in the
Investigator's opinion, may interfere with protocol adherence or a subject's ability
to give informed consent